Clinical trials: Infections, Bacterial
Onychomycosis
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25…
- Trial name
- NCT00680160
- Testing
- AN2690
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Bacterial Vaginosis
Pharmacokinetic Study of DARE-BV1
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT05354050
- Testing
- DARE-BV1
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Onychomycosis
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus.
- Trial name
- NCT00443820
- Testing
- terbinafine
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 526 people
- Sponsor
- Novartis Pharmaceuticals
Interdigital Tinea Pedis
Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show…
- Trial name
- BNF-0909 (NCT01119742)
- Testing
- Butenafine Hydrochloride 1%, Butenafine Hydrochloride 1% B, Vehicle A
- Volunteers
- 428 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Infections, Bacterial
A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects
This study is an open-label, randomized, single dose, four period, balanced crossover study to assess in eligible healthy male or female subjects.
- Trial name
- NCT01648179
- Testing
- GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonic Plague, Preventive Therapy
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V
The purpose of this study is to evaluate the safety and tolerability of a two-dose schedule of the recombinant plague vaccine rF1V in healthy volunteers when given as an intramuscular (IM) injection at four ascending dose-levels.
- Trial name
- NCT00097396
- Testing
- rF1V vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Diarrhea
ETEC Logistics Trial (TREK)
This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate the epidemiology of natural infection with ETEC occurring after transcutaneous immunization in a field setting.
- Trial name
- Trek (NCT00516659)
- Testing
- Heat-Labile Enterotoxin of Escherichia coli (LT)
- Where
- 19 sites in United States, Guatemala and 1 more
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Tetanus, Diphtheria
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first…
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- NCT00347958
- Testing
- Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 545 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pulmonary Tuberculosis
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for…
- Trial name
- NCT05359315
- Testing
- Interferon-Gamma
- Where
- Russia
- Volunteers
- 84 people
- Sponsor
- SPP Pharmaclon Ltd.
Bacterial Infections, Gram-Positive Bacterial Infections
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
- Conditions
- Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
- Trial name
- NCT00037050
- Testing
- Linezolid, Vancomycin, Oxacillin
- Volunteers
- 739 people
- Sponsor
- Pfizer
Bacterial Vaginosis, Yeast Infection
A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.
This virtual randomized controlled trial evaluates the efficacy of a prebiotic and probiotic supplement in providing relief from symptoms associated with bacterial vaginosis and yeast infections.
- Trial name
- NCT06665126
- Testing
- Prebiotic + Probiotic Supplement
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Happy V
End Stage Renal Disease
HeRO Vascular Access Device Post Market Procedural Survey Protocol
Post market observational survey of a vascular access device for access-challenged patients. Data collection efforts focused on patient medical and access history and implant procedure results.
- Trial name
- PPS (NCT00889291)
- Volunteers
- 77 people
- Sponsor
- Merit Medical Systems, Inc.
Gram-Positive Bacterial Infections
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients.
- Trial name
- NCT00240747
- Testing
- Synercid
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Tuberculosis
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis…
- Trial name
- NCT02391415
- Testing
- VPM1002, BCG, VPM1002(Hyg+)
- Where
- 4 sites in South Africa
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing…
- Trial name
- ENCORE (NCT03597347)
- Testing
- Molgramostim nebulizer solution, PARI eFlow nebulizer system
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Savara Inc.
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06959225
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 580 people
- Sponsor
- Incyte Corporation
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
- Trial name
- NCT03574389
- Testing
- 13vPnC, Hib
- Where
- 2 sites in China
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Infections
Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates
The main objective will be to test the safety of two intravenous infusions of Altastaph, a human immunoglobulin product. The study will also test the ability of Altastaph to protect against S. aureus infection.
- Trial name
- NCT00066989
- Testing
- Staphylococcus aureus Immune Globulin (Human) 5%
- Volunteers
- 200 people
- Sponsor
- Nabi Biopharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.